Cytokine receptor signaling pathways

Journal of Allergy and Clinical Immunology

Volumn 105, Issue 5, 2000, Pages 877-888

  Leonard, Warren J ^a   Lin, Jian Xin ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cytokine; Cytokine receptor; IL 2; Jak kinases; STAT proteins; XSCID

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 2; PROTEIN TYROSINE KINASE;

CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; IMMUNE DEFICIENCY; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034029101     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2000.106899     Document Type: Article

References (112)

1. 1. Cohen S, Bigazzi PE, Yoshida T. Commentary: similarities of T cell function in cell-mediated immunity and antibody production. Cell Immunol 1974;12:150-9.
2. 2. Leonard WJ. Type I cytokines and interferons and their receptors. In: Paul WE, editor. Fundamental immunology, 4th ed. Philadelphia: Lippincott-Raven; 1999. p 741-4.
3. 3. Sprang SR. Bazan JF. Cytokine structural taxonomy and mechanisms of receptor engagement. Curr Opin Struct Biol 1993;3:815-27.
4. 4. Davies DR, Wlodawer A. Cytokines and their receptor complexes. FASEB J 1995;9:50-6.
5. 5. De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992;255:306-12.
6. 6. Ward LD, Howlett GJ, Discolo G, Yasukawa K, Hammacher A, Moritz RL, et al. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem 1994;269:23286-9.
7. 7. Davis S, Aldrich TH, Stahl N, Pan L, Taga T, Kishimoto T, et al. LIFRβ and gp130 as heterodimerizing signal transducers off the tripartite CNTF receptor. Science 1993;260:1805-8.
8. 8. Darnell JE Jr, Kerr IM, Stark, GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
9. 9. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-5.
10. 10. STATs: signal transducers and activators of transcription. Cell 1996; 84:331-4.
11. 11. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322.
12. 12. Horvath CM, Darnell JE Jr. The state of the STATs: recent developments in the study of signal transduction to the nucleus. Curr Opin Cell Biol 1997;9:233-9.
13. 13. Johnston JA, Kawamura M, Kirken RA, Chen YQ. Blake TB, Shibuya K, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994;370:151-3.
14. 14. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 1994:370:153-7.
15. 15. Russell SM, Johnston JA, Noguchi M, Kawamura M, Bacon CM, Friedmann M, et al. Interaction of IL-2Rβ and χ chains with Jak1 and Jak3: implications for XSCID and XCID. Science 1994;266:1042-5.
16. 16. Boussiotis VA, Barber DL, Nakarai T, Freeman GJ, Gribben JG, Bernstein GM, et al. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 1994;266:1039-42.
17. 17. Miyazaki T, Kawahara A, Fujii H, Nakagawa Y, Minami Y, Liu ZJ, et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994;266:1045-7.
18. 18. Greenlund AC, Morales MO, Viviano BL, Yan H, Krolewski J, Schreiber RD. Stat recruitment by tyrosine phosphorylated cytokine receptors: an ordered reversible affinity-driven process. Immunity 1995;2:677-87.
19. 19. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE Jr, Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998;93:827-39.
20. 20. Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998;394:145-51.
21. 21. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-50.
22. 22. Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 1998;273:30218-24.
23. 23. Look DC, Pelletier MR, Tidwell RM, Roswit WT, Holtzman MJ. Stat1 depends on transcriptional synergy with Spl. J Biol Chem 1995; 270:30264-7.
24. 24. Shaefer TS, Sanders LK, Nathans D. Cooperative transcriptional activity of Jun and Stat3β, a short form of Stat3. Proc Natl Acad Sci U S A 1995;92:9097-101.
25. 25. Stocklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 1996;383:726-8.
26. 26. Cella N, Groner B, Hynes NE. Characterisation of Stat5a and Stat5b homodimers and heterodimers and their association with the glucocorticoid receptor in mammary cells. Mol Cell Biol 1998;18:1783-92.
27. 27. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, et al. Cooperation of Stat2 and p300/CBP in signalling induced by interferon α. Nature 1996;383:344-7.
28. 28. Gingras S, Simard J, Groner B. Pfitzner E. p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6. Nucleic Acids Res 1999;27:2722-9.
29. 29. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JE Jr. Two contact regions between Stat1 and CBP/p300 in interferon γ signaling. Proc Natl Acad Sci U S A 1996;93:15092-6.
30. 30. Pfitzner E, Jahne R, Wissler M, Stoecklin E, Groner B. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transaction domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Mol Endocrinol 1998;12:1582-93.
31. 31. Zhu M, John S, Berg M, Leonard WJ. Functional association of Nmi with Stat5 and Stat5 in IL-2-and IFN γ-mediated signaling. Cell 1999;96:121-30.
32. 32. Xu X, Sun Y-L, Hoey T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino terminal domain. Science 1996;273:794-7.
33. 33. Vinkemeier U, Cohen SL, Moarefi I, Chait BT, Kuriyan J, Darnell JE Jr. DNA binding of in vitro activated Stat1a, Stat1b and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J 1996;15:5616-26.
34. 34. Vinkemeier U, Moarefi I, Darnell JE Jr, Kuriyan J. Structure of the amino-terminal protein interaction domain of STAT-4. Science 1998;279:1048-52.
35. 35. John S, Vinkemeier U, Soldaini E, Darnell JE Jr, Leonard WJ. The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol 1999;19:1910-8.
36. 36. Leonard WJ. The molecular basis of X-linked combined immunodeficiency: defective cytokine receptor signaling. Annu Rev Med 1996;47:229-39.
37. 37. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, et al. Interleukin-2 receptor chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993;73:147-57.
38. + severe combined immunodeficiency. Nat Genet 1998;20:394-7.
39. 39. Puel A, Leonard WJ. Interleukin-7 receptor a chain dependent signaling is required for T-cell development: basis for T-B+NK+ severe combined immunodeficiencies in humans. Immunol Allergy Clin. 2000; 20(Suppl):51-63.
40. 40. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, et al. TL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998;9:669-76.
41. 41. Leonard WJ, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ, et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 1984;311:626-31.
42. 42. Nikaido T, Shimizu A, Ishida N, Sabe H, Teshigawara K, Maeda M, et al. Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature 1984;311:631-5.
43. 43. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994;13:2822-30.
44. 44. Macchi P, Villa A, Gillani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377:65-8.
45. 45. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270:797-800.
46. 46. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, Russell SM, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity 1995;2:223-38.
47. 47. DiSanto JP, Müller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin-2 receptor γ chain. Proc Natl Acad Sci U S A 1995;92:377-81.
48. 48. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995;270:794-7.
49. 49. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, et al. Defective lymphoid development in mice lacking Jak3. Science 1995;270:800-2.
50. 50. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N, et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995;3:771-82.
51. 51. Suzuki K, Nakajima H, Saito Y, Saito Y, Leonard WJ, Iwamoto I. Janus kinase 3 (Jak3) is essential for common cytokine receptor γ chain (γ c) dependent signaling: comparative Analysis of γc. Jak3, and γc and Jak3 double-deficient mice. Int Immunol 2000;12:123-32.
52. 52. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 1995;268:1472-6.
53. 53. Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 deficient mice. Science 1991;254:707-10.
54. 54. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245-8.
55. 55. Lin J-X, Migone T-S, Tsang M, Friedmann M, Weatherbee JA, Zhou L, et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995;2:331-9.
56. 56. Lischke A, Moriggl R, Brandlein S, Berchtold S, Kammer W, Sebald W, et al. The interleukin-4 receptor activates STAT5 by a mechanism that relies upon common gamma-chain. J Biol Chem 1998;273:31222-9.
57. 57. Soldaini E, John S, Moro S, Bollenbacher J, Schindler U, Leonard WJ. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol 2000;20:389-401.
58. 58. Lin J-X, Mietz J, Modi WS, John S, Leonard WJ. Cloning of human Stat5B: reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J Biol Chem 1996;271:10738-44.
59. 59. Lin J-X, Leonard WJ. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev 1997;8:313-32.
60. 60. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996;4:313-9.
61. 61. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996;380:630-3.
62. 62. Nakajima H, Liu XW, Wynshaw-Boris A, Rosenthal LA, Imada K, Finbloom DS, et al. An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor a chain induction. Immunity 1997;7:691-701.
63. 63. Imada K, Bloom ET, Nakajima H, Horvath-Arcidiacono JA, Udy GB, Davey HW, et al. StatSb is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med 1998;188:2067-74.
64. 64. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999;10:249-59.
65. 65. Akaishi H, Takeda K, Kaisho T, Shineha R, Satomi S, Takeda J, et al. Defective IL-2-mediated IL-2 receptor alpha chain expression in Stat3-deficient T lymphocytes. Int Immunol 1998;10:1747-51.
66. 66. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997;11:179-86.
67. 67. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park S-H, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 1997;94:7239-44.
68. 68. Yu CR, Ortaldo JR, Curiel RE, Young HA, Andersen SK, Gosselin P. Role of a STAT binding site in the regulation of the human perform promoter. J Immunol 1999;162:2785-90.
69. 69. Zhang J, Scordi I, Smyth MJ, Lichtenheld MG. Interleukin 2 receptor signaling regulates the perform gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med 1999;190:1297-308.
70. 70. Lowin B, Beermann F, Schmidt A, Tschopp J. A null mutation in the perforin gene impairs cytolytic T lymphocyte-and natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 1994;91:11571-5.
71. 71. Kagami S-I, Nakajima H, Kumano K, Suzuki K, Suto A, Imada K, et al. Both Stat5a and Stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue. Blood 2000;95:1370-7.
72. 72. Sperisen P, Wang SM, Soldaini E, Pla M, Rusterholz C, Bucher P, et al. Mouse interleukin-2 receptor a gene expression: interleukin-1 and interleukin-2 control transcription via distinct cis-acting elements. J Biol Chem 1995;270:10743-53.
73. 73. John S, Robbins CM, Leonard WJ. An IL-2 response element in the human IL-2 receptor a chain promoter is a composite element that binds Stat5, Elf-1, HMG-I(Y) and a GATA family protein. EMBO J 1996;15:5627-35.
74. 74. Lecine P, Algarte M, Rameil P, Beadling C, Bucher P, Nabholz M, et al. Elf-1 and Stat5 bind to a critical element in a new enhancer of the human interleukin-2 receptor a gene. Mol Cell Biol 1996;16:6829-40.
75. 75. Migone T-S, Lin J-X, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995;269:79-81.
76. 76. Takemoto S, Mulloy JC, Cereseto A, Migone T-S, Patel BK, Matsuoka M, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci U S A 1997;94:13897-902.
77. 77. Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by the v-abl oncogene. Science 1995;269:1875-7.
78. 78. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
79. 79. Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, et al. Requirement for Ras/RacI-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 1999;19:7519-28.
80. 80. Graves JD, Downward J, Izquierdo-Pastor M, Rayter S, Warne PH, Cantrell DA. The growth factor IL-2 activates p21 ras proteins in normal human T lymphocytes. J Immunol 1992;148:2417-22.
81. 81. Turner B, Rapp U, App H, Greene M, Dobashi K, Reed J. Interleukin 2 induces tyrosine phosphorylation and activation of p72-74 Raf-1 kinase in a T-cell line. Proc Natl Acad Sci U S A 1991;88:1227-31.
82. 82. Turner BC, Tonks NK, Rapp UR, Reed JC. Interleukin 2 regulates Raf-I kinase activity through a tyrosine phosphorylation-dependent mechanism in a T-cell line. Proc Natl Acad Sci U S A 1993;90:5544-8.
83. 83. Zmuidzinas A, Mamon HJ, Roberts TM, Smith KA. Interleukin-2-triggered Raf-1 expression, phosphorylation, and associated kinase activity increase through G1 and S in CD3-stimulated primary human T cells. Mol Cell Biol 1991;11:2794-803.
84. 84. Remillard B, Petrillo R, Maslinski W, Tsudo M, Strom TB, Cantley L, et al. Interleukin-2 receptor regulates activation of phosphatidylinositol 3-kinase. J Biol Chem 1991;266:14167-70.
85. 85. Merida I, Diez E, Gaulton GN. IL-2 binding activates a tyrosine-phosphorylated phosphatidylinositol-3-kinase. J Immunol 1991;147:2202-7.
86. 86. Augustine JA, Sutor SL, Abraham RT. Interleukin 2-and polyomavirus middle T antigen-induced modification of phosphatidylinositol 3-kinase activity in activated T lymphocytes. Mol Cell Biol 1991;11:4431-40.
87. 87. Migone T-S, Rodig S, Cacalano NA, Berg M, Schreiber RD, Leonard WJ. Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation. Mol Cell Biol 1998;18:6416-22.
88. 88. Friedmann MC, Migone T-S, Russell SM, Leonard WJ. Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation. Proc Natl Acad Sci U S A 1996;93:2077-82.
89. 89. Ravichandran KS, Burakoff SJ. The adapter protein Shc interacts with the interleukin-2 (IL-2) receptor upon IL-2 stimulation. J Biol Chem 1994;269:1599-602.
90. 90. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U S A 1997;94:3627-32.
91. 91. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992;358:70-3.
92. 92. Hatakeyama M, Kono T, Kobayashi N, Kawahara A, Levin SD, Perlmutter RM, et al. Interaction of the IL-2 receptor with the src-family kinase p56lck: identification of novel intermolecular association. Science 1991;252:1523-8.
93. 93. Kobayashi N, Kono T, Hatakeyama M, Minami Y, Miyazaki T, Perlmutter RM, et al. Functional coupling of the src-family protein tyrosine kinases p59fyn and p53/561yn with the interleukin 2 receptor: implications for redundancy and pleiotropism in cytokine signal transduction. Proc Natl Acad Sci U S A 1993;90:4201-5.
94. 94. Minami Y, Nakagawa Y, Kawahara A, Miyazaki T, Sada K, Yamamura H, et al. Protein tyrosine kinase Syk is associated with and activated by the IL-2 receptor: possible link with the c-myc induction pathway. Immunity 1995;2:89-100.
95. 95. Miyazaki T, Takaoka A, Nogueira L, Dikic I, Fujii H, Tsujino S, et al. Pyk2 is a downstream mediator of the IL-2 receptor-coupled Jak signaling pathway. Genes Dev 1998;12:770-5.
96. 96. Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 1996;273:1717-9.
97. 97. Haspel RL, Salditt-Georgieff M, Darnell JE Jr. The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J 1996;15:6262-8.
98. 98. Haspel RL, Darnell JE Jr. A nuclear protein tyrosine phosphatase is required for the inactivation of Stall. Proc Natl Acad Sci U S A 1999;96:10188-93.
99. 99. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, Shuai K. Inhibition of Stall-mediated gene activation by PIAS1: inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 1998;95:10626-31.
100. 100. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278:1803-5.
101. 101. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995;14:2816-26.
102. 102. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-21.
103. 103. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387:921-4.
104. 104. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-9.
105. 105. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A 1998;95:114-9.
106. 106. Matsumoto A, Seki Y, Kubo M, Ohtsuka S, Suzuki A, Hayashi I, et al. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 1999;19:6396-407.
107. 107. Aman MJ, Migone T-S, Sasaki A, Ascherman DP, Zhu M-h, Soldaini E, et al. CIS associates with the interleukin-2 receptor a chain and inhibits IL-2-dependent signaling. J Biol Chem 1999;274:30266-72.
108. 108. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, et al. SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999;98:597-608.
109. 109. Marine J-C, Topham DJ, McKay C. Wang D, Parganas E, Stravopodis D, et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 1999;98:609-16.
110. 110. Marine J-C, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H, et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 1999b;98:617-27.
111. 111. Kovanen PE, Leonard WJ. Cytokine signaling: inhibitors keep cytokines in check. Curr Biol 1999;9:R899-902.
112. 112. Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM. Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Them 1999;274:22484-92.